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Abstract
Background Studies on colorectal cancer (CRC) screen-
ing and incidence among American Indian/Alaska Natives
(AI/AN) are few.
Aims Our aim was to determine CRC screening preva-
lence and to calculate CRC incidence among AI/AN
receiving care within the Indian Health Service (IHS).
Methods A retrospective cohort study of AI/AN who
utilized IHS from 1996 to 2004. AI/AN who were average-
risk for CRC and received primary care within IHS were
identiﬁed by searching the IHS Resource Patient Manage-
ment System for selected ICD-9/CPT codes (n = 142,051).
CRC screening prevalence was calculated and predictors of
screening were determined for this group. CRC incidence
rates were ascertained for the entire AI/AN population ages
50–80 who received IHS medical care between 1996 and
2004 (n = 283,717).
Results CRCscreeningwasperformedin4.0%ofaverage-
risk AI/AN. CRC screening was more common among
women than men (RR = 1.6, 95% CI 1.4–1.7) and among
AI/AN living in the Alaska region compared to the Paciﬁc
Coast region (RR = 2.5, 95% CI 2.2–2.8) while patients
living in the Northern Plains (RR = 0.4, 95% CI 0.3–0.4)
were less likely to have been screened. CRC screening was
less common among patients with a greater number of pri-
marycarevisits.Theage-adjustedCRCincidenceamongAI/
AN ages 50–80 was 227 cancers per 100,000 person-years.
Conclusions CRC was common among AI/AN receiving
medicalcarewithinIHS.However,CRCscreeningprevalence
was far lower than has been reported for the U.S. population.
Keywords Screening  Incidence  Colonoscopy 
Health disparity
Introduction
Colorectal cancer (CRC) is a leading cause of morbidity
and mortality among American Indian/Alaskan Natives
(AI/AN) [1]. AI/AN have more advanced disease [2] and
lower survival rates [3], and there has been no change in
CRC mortality rates over the last decade for AI/AN [4].
One important question that warrants further attention is
how well CRC screening services are provided to AI/AN.
While there are more data assessing CRC screening and
development of screening programs for Hispanics [5, 6],
Asians [7, 8], and African–Americans [9–11], there are few
studies that report the CRC screening experience of AI/AN.
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numbers of AI/AN included, racial misclassiﬁcation, and
methodological problems [4, 12–14].
Such gaps in knowledge may exacerbate existing dis-
parities in cancer control programs and in the reliability of
measures of disease burden between AI/AN and other
ethnic groups. The development and evaluation of inter-
ventions to increase screening and lower CRC-related
mortality in the AI/AN community hinge on reliable data
on screening and incidence. Our study aims were to
determine CRC screening prevalence among average-risk
AI/AN ages 50–80 who received primary care within the
Indian Health Service (IHS) and to estimate CRC incidence
among AI/AN IHS health care users.
Methods
Data Source
IHS is an agency of the U.S. Department of Health and
Human Services that provides health care services to
members of federally recognized AI/AN tribes. IHS uti-
lizes the Resource and Patient Management System
(RPMS) to store patient demographics, create electronic
medical records, and record and manage patient billing
information. RPMS data for each calendar year from
1996–2004 were merged into a single dataset representing
all IHS patients ages 50—–80 from 1996 to 2004.
AI/AN Cohort That Used IHS as Their Primary Source
of Health Care
AI/AN patients C50 years by December 31, 2004 who
received their primary care from IHS between January 1,
1999 and December 31, 2004 were identiﬁed. Patients were
identiﬁed who had one visit to a primary care clinic between
January1,2004andDecember31,2004andwhohadanother
primary care clinic visit within the preceding 5 years (Jan-
uary 1, 1999 through December 31, 2003). A primary care
clinic included Cancer Screening, Chronic Disease, Diabe-
tes, Internal/General Medicine, Elder Care, Family Practice,
Gastroenterology/Hepatology, General Preventative, Men’s
and Women’s Health Screening, Obstetrics/Gynecology,
Traditional Medicine, or Wellness clinics. These clinics
have beenpreviouslydeﬁned asprimarycareclinicsinother
studies [15]orprovidedequivalentprimarycarewithin IHS.
Deﬁning Average-Risk AI/AN for Colorectal Cancer
Patients were excluded from the CRC screening analysis if
they were considered at increased risk for colorectal cancer
[16]. Patients were excluded if they were\50 years of age
at the time they underwent a CRC screening test, had a
diagnosis of colorectal cancer/colonic polyps prior to CRC
screening, and/or a diagnosis of ulcerative colitis/Crohn’s
disease deﬁned using International Clinical Diagnosis
(ICD)-9 code(s) codes [17] recorded at any point between
January 1, 1996 through December 31, 2004. Patients
were excluded if they had speciﬁc symptoms (Table 1)a t
any time prior to a CRC screening method that prompted an
endoscopic evaluation other than for screening purposes.
AI/AN who Underwent Colorectal Cancer Screening
The screening eligible cohort consisted of patients who
received primary care within IHS from 1999 to 2004, and
who were considered at average-risk for CRC. Among this
cohort of patients, it was then determined which ones had
undergone a CRC screening test by searching the dataset for
selected ICD-9 and/or Current Procedural Terminology
(CPT) codes [18] (Table 1). To qualify as having been
screened, a patient had to have undergone (according to the
following hierarchy) at least one colonoscopy during 1996–
2004, one ﬂexible sigmoidoscopy during 2000–2004, one
double contrast barium enema (DCBE) during 2000–2004,
oronefecaloccultbloodtest(FOBT)during2003–2004.Ifa
patient received multiple screening tests, the most recent
date and method was selected as the time of screening.
A sensitivity analysis was then performed by (1) varying
our timeframe for methods included for CRC screening,
and (2) altering the CRC screening cohort eligibility
inclusion criteria in order to determine if these changes
inﬂuenced CRC screening prevalence. First, the CRC
screening deﬁnition was modiﬁed by eliminating any
timeframe for receipt of any of the recommended screening
tests. Secondly, the CRC screening cohort eligibility cri-
teria was varied while at the same time continuing the
original deﬁnition of screening.
Detection of New Cases of Colorectal Cancer
The entire population of 283,717 AI/AN patients between
ages 50–80 who received medical care within IHS between
1996–2004wereincludedintheCRCincidenceanalysis.We
searched for ICD-9 codes that represented colon and rectal
cancer (Table 1). The ﬁrst documentation of an ICD-9 code
for either cancer represented the year of initial diagnosis. A
patient could only be counted once as having CRC.
Data Abstracted
Data collected on patients included age at the time of
screening/CRCdiagnosis,sex,IHSgeographicregionwhere
the patient received screening/CRC diagnosis, number of
comorbid medical conditions, and number of primary care
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123visits. IHS geographic regions were categorized as follows:
Alaska, Paciﬁc Coast (California, Oregon, Washington,
Idaho), Southwest (Nevada, Colorado, Arizona, Utah, New
Mexico), Northern Plains (North Dakota, South Dakota,
Nebraska,Iowa,Minnesota,Wisconsin,Michigan,Montana,
Wyoming), and East (Kansas, Oklahoma, Texas, Louisiana,
Alabama, Tennessee, South Carolina, Florida, New York,
Maine, Pennsylvania, Massachusetts, Rhode Island, Con-
necticut). These geographic regions have been used in pre-
viouspublications[19,20].Todetermineco-morbidmedical
conditions ICD-9 codes were counted according to the
Agency for Healthcare Research and Quality codebook [21].
Inordertopreventbiasduetovariationinobservationtime,in
the univariate analysis the average number of co-morbid
medicalconditionsperyear(andprimarycarevisitsperyear)
is reported. For the Poisson regression model, co-morbid
medical conditions and primary care visits were modeled as
theactualnumberofmedicalconditions(orvisits)persubject
per age group per period.
Statistical Analysis
CRC screening prevalence was calculated by dividing the
number of patients that underwent CRC screening by the
number of eligible, average-risk IHS patients. Unadjusted
estimates within demographic subgroups (i.e. sex, age, etc.)
and their exact binomial conﬁdence intervals were calcu-
lated. A Pearson’s chi-square test was used to assess the
statistical association between CRC screening and demo-
graphic subgroups. In order to ascertain the effect of
demographic and clinical variables on CRC screening
multivariable Poisson regression models were built. The
models assumed all subjects had the same follow up time
within each calendar period. A P value of less than 0.05
was considered statistically signiﬁcant.
CRC incidence rates were calculated by dividing the
number of new CRC cases by the number of all patients
followed in our combined datasets from 1996 to 2004
(expressed as 100,000 person-years). CRC incidence rates
were age-adjusted by 6 age groups (50–54, 55–59, 60–64,
65–70, 71–74, and 75–80 years) by the direct method using
the 2000 U.S. standard population [22]. All analyses were
performed using SAS
 software (version 9.1.3; SAS
Institute, Cary, North Carolina).
The study protocol was approved by the University of
California, San Francisco Committee on Human Research
and the National IHS Institutional Review Board.
Results
Baseline Demographics
The nine yearly datasets (1996–2004) comprised 283,717
unique patients. A total of 141,666 patients were excluded
(49.9%) from the analysis of colorectal cancer screening.
Table 1 ICD-9 and CPT codes used to identify CRC screening methods, colorectal cancer/colonic polyps, and several exclusion criteria
ICD-9 codes CPT codes
CRC screening method
Colonoscopy 453.25, 453.55, 453.78, 453.80, 453.81, 453.83, 453.84, 453.85,
443.88, 443.89, 443.92, 443.93, 443.94, G0121, G0105
45.22, 45.23, 45.25,
45.42, 45.43
Flexible sigmoidoscopy/
Rigid proctosigmoidoscopy
453.00, 453.05, 453.08, 453.09, 453.15, 453.20, 453.30, 453.31,
453.33, 453.35, 453.38, 453.39, G0104
45.24, 48.22, 48.23,
48.24, 48.26, 48.36
Double-contrast barium enema 742.80, 742.75, 742.70, G0106, G0120, G0122 87.64
Fecal occult blood testing 822.70, 822.71, 822.72, 822.74, 892.05, G0107, G0328, G0394 N/A
Colorectal cancer/Colonic polyp
Colon cancer 153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7, 153.8,
153.9, 197.5, V10.05, 230.3
N/A
Rectal cancer 154.0, 154.1, V10.06, 230.4 N/A
Colonic polyp 211.3, 211.4 N/A
Excluding symptoms/diseases
Anemia 280.0, 280.9 N/A
Constipation 564.00 N/A
Diarrhea 787.91, 564.5 N/A
Abdominal pain 555.1, 789.00, 789.01, 789.02, 789.03, 789.04, 789.05, 789.06, 789.07 N/A
Hematochezia/Melena 578.1 N/A
Crohn’s disease 555.0, 555.1, 555.2, 555.3, 555.4, 555.5, 555.6, 555.7, 555.8, 555.9 N/A
Ulcerative colitis 556.0, 556.1, 556.2, 556.3, 556.4, 556.5, 556.6, 556.7, 556.8, 556.9 N/A
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123The majority of patients were excluded because they did
not meet our deﬁnition of receiving primary care within
IHS (Fig. 1). The primary study population consisted of
142,051 average-risk patients; 54.5% of patients were aged
50–54 years at their ﬁrst IHS medical visit and were female
(59.5%) (Table 2).
Colorectal Cancer Screening Prevalence
Of 142,051 AI/AN patients considered at average-risk for
CRC, 5,661 patients underwent recommended CRC
screening between 1996 and 2004 for a screening preva-
lence of 4.0%. Among average-risk patients who under-
went CRC screening 1.9% underwent FOBT in 2003–2004,
1.1% had a double-contrast barium enema between 2000
and 2004, 0.7% underwent colonoscopy between 1996 and
2004, and 0.3% had a ﬂexible sigmoidoscopy between
2000 and 2004 (see Fig. 1). Women and patients residing
in the Alaska and East regions had the highest CRC
screening prevalence (Table 3). The methods utilized for
screening varied by geographic region (Fig. 2).
CRC Screening Sensitivity Analysis
If average-risk IHS AI/AN patients underwent any rec-
ommended CRC screening method at any time from 1996
to 2004, 5,860 patients were screened for a prevalence of
4.1% (95% conﬁdence interval 4.0–4.2%). If we changed
our primary care deﬁnition to include patients who had a
primary care visit in both 2004 and 2003, our CRC
screening prevalence was 4.1% (95% CI 4.0–4.2%). Our
CRC screening prevalence was 4.0% if we did not exclude
patients with symptoms. Lastly, if no restrictions were
placed on inclusion into our screening eligible cohort
then CRC screening prevalence was 10.0% (95% CI
9.9–10.1%).
Colorectal Cancer Screening Predictors
Independent predictors of CRC screening were sex
(RR = 1.6, 95% CI 1.4–1.5 for women compared to men),
and geographic region. In particular, patients residing in
the Alaska region were more likely to be screened
Colonoscopy ICD-9/CPT codes documented 
between 1996-2004?
Flexible sigmoidoscopy ICD-9/CPT codes 
documented between 2000-2004? 
Double contrast barium enema ICD-9/CPT 
codes documented between 2000-2004?
1,001 (0.7%) patients in 
colonoscopy screening cohort 
465 (0.3%) patients in flexible 
sigmoidoscopy screening 
cohort
Yes 
Fecal occult blood test ICD-9/CPT codes 
documented between 2003-2004? 
136,390 patients in unscreened cohort, 1996-
2004
1,515 (1.1%) patients in DCBE 
screening cohort 
2,680 (1.9%) patients in FOBT 
screening cohort 
5,661 (4.0%) patients in CRC 
screening cohort, 1996-2004 
Yes 
Yes 
Yes 
No 
No
No
No 
283, 717 patients included in 1996-2004 IHS RPMS dataset 
141,666 patients were excluded 
       137,753 less than 2 primary care visits from 1999-2004 
       2,397 symptoms prompting further endoscopy 
       1,364 Inflammatory bowel disease 
      152 CRC/colonic polyps detected prior to CRC screening
142,051 average-risk IHS AI/AN patients eligible for CRC screening 
Fig. 1 Flow diagram of
determining whether or not
eligible, average-risk AI/AN
patients, aged 50–80 years,
underwent CRC screening in
IHS from 1996–2004
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123compared to patients in the Paciﬁc Coast (RR = 2.5, 95%
CI 2.2–2.8), while patients living in the Northern Plains
(RR = 0.4, 95% CI 0.3–0.4) and Southwest (RR = 0.5,
95% CI 0.5–0.6) were less likely to have been screened.
There was a trend toward increased screening with a
greater number of co-morbid medical conditions, although
this did not reach statistical signiﬁcance. In addition, CRC
screening appeared lower in patients who had an increasing
number of primary care medical visits (Table 4).
Colorectal Cancer Incidence
There were 3,558 new cases of colorectal cancer (2,684
colon and 874 rectal) documented among the 283,717
AI/AN patients analyzed. The colon cancer incidence rate
was 183 cancers per 100,000 person-years while for rectal
cancer it was 60 cancers per 100,000 person-years.
The age-adjusted CRC incidence rate for AI/AN aged
Table 2 Demographic information on average-risk AI/AN IHS
patients, aged 50–80 years
Demographic
Information
Number of eligible
patients (%)
Sex
a
Female 84,505 (59.5)
Male 57,529 (40.5)
Age at ﬁrst IHS medical visit (years)
50–54 77,449 (54.5)
55–59 24,954 (17.6)
60–64 19,607 (13.8)
65–69 13,220 (9.3)
70–74 6,222 (4.4)
75–80 599 (0.4)
IHS geographic region
Southwest 44,880 (31.6)
East 41,551 (29.3)
Northern Plains 26,949 (19.0)
Paciﬁc Coast 16,690 (11.7)
Alaska 11,981 (8.4)
Average number of comorbid medical conditions per year
None 3,647 (2.6)
One 7,672 (5.4)
Two 15,492 (10.9)
Three or more 115,240 (81.1)
Average number of medical visits per calendar year
b
One 8,404 (5.9)
Two 19,428 (13.7)
Three or more 114,219 (80.4)
a 17 patients had an unknown sex
b Includes any IHS primary care medical visit
Table 3 Number of colorectal cancer screening examinations among
eligible, average-risk AI/AN IHS patients, aged 50–80 years, from
1996 to 2004
Variable All CRC screening methods
a
(%, 95% conﬁdence interval)
Sex
b
Female 3,840 (4.5, 4.4–4.7)
Male 1,821 (3.2, 3.0–3.3)
Age at CRC screening (years)
b
50–54 1,701 (2.2, 2.1–2.3)
55–59 1,271 (2.1, 2.0–2.2)
60–64 1,075 (2.2, 2.1–2.3)
65–69 818 (2.3, 2.1–2.4)
70–74 554 (2.5, 2.3–2.7)
75–80 242 (2.7, 2.4–3.0)
IHS geographic region
b
Alaska 1,178 (9.8, 9.3–10.4)
East 2,176 (5.2, 5.0–5.5)
Paciﬁc Coast 789 (4.7, 4.4–5.1)
Southwest 1,043 (2.3, 2.2–2.5)
Northern Plains 475 (1.8, 1.6–1.9)
Average number of comorbid medical conditions per calendar year
b
None 19 (0.5, 0.3–0.8)
One 276 (3.6, 3.2–4.0)
Two 692 (4.5, 4.1–4.8)
Three or more 4,674 (4.1, 3.9–4.2)
Average number of primary care visits per calendar year
b,c
One 358 (4.3 3.8–4.7)
Two 935 (4.8, 4.5–5.1)
Three or more 4,368 (3.8, 3.7–3.9)
Calendar year
1996
d 0
1997
d 0
1998
d 0
1999
d 27 (0.03, 0.02–0.05)
2000
e 2,044 (2.5, 2.4–2.6)
2001
e 239 (0.3, 0.3–0.3)
2002
e 230 (0.3, 0.2–0.3)
2003
f 1,727 (2.0, 1.9–2.1)
2004
f 1,394 (1.7, 1.6–1.7)
Overall CRC screening 5,661 (4.0, 3.9–4.1)
a Includes average-risk patients who underwent colonoscopy, ﬂexible sig-
moidoscopy, double-contrast barium enema, or fecal occult blood test for
screening purposes
b Differences between variables within subgroup were statistically signiﬁ-
cant, P\0.001
c Primary care visits include patients with medical encounters in the fol-
lowing clinics: Cancer Screening, Chronic Disease, Diabetes, Internal/
General Medicine, Elder Care, Family Practice, Gastroenterology/Hepatol-
ogy, General Preventative, Men’s and Women’s Health Screening, Obstet-
rics/Gynecology, Traditional Medicine, or Wellness clinics
d Screening method includes only colonoscopy
e Screening method includes colonoscopy, DCBE, or ﬂexible
sigmoidoscopy
f Screening method includes colonoscopy, DCBE, ﬂexible sigmoidoscopy,
or FOBT
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12350–80 years in our IHS RPMS database was 227 colorectal
cancers per 100,000 person-years. Colorectal cancer was
slightly more common in AI/AN men than women and in
those individuals with a greater number of comorbid
medical conditions and IHS medical care visits. Age was
associated with CRC incidence with older AI/AN indi-
viduals more likely to have colorectal cancer than younger
patients. Additionally, CRC was less common among
patients who had undergone screening. Interestingly CRC
incidence was associated with geographic region. For
example, AI/AN living in Alaska were three times more
likely to have CRC detected when compared to residents of
other IHS regions (Table 5).
Discussion
To our knowledge, this is the ﬁrst study to investigate CRC
screening prevalence and predictors in a large, national
cohort of AI/AN. Our study determined that only 4.0% of
asymptomatic, average-risk AI/AN receiving IHS medical
care underwent recommended CRC screening between
1996 and 2004. Women and residents of the Alaska region
were more likely to have been screened, but even among
women in this region screening was only undertaken 10.8%
of the time.
The CRC screening prevalence we detected is below
previously published results for AI/AN [4, 12, 14, 23, 24]
and below those for the overall U.S. population [25]. While
there is marked variation in the reported prevalence of
CRC screening among AI/AN, with estimates ranging from
26 to 44% [4, 12, 13], all these estimates exceeded what we
discovered. Methodological designs of past studies may in
part explain their elevated reported screening compared to
ours. CRC screening estimates from previous studies
encompassing a similar timeframe as ours are largely based
on telephone surveys and patient self-reported question-
naires which introduce recall and selection biases and
examine a distinct group of AI/AN who had access to land-
line telephones, spoke and understood English and were
willing to participate [14]. Furthermore, some of these
studies focused on a small sample of AI/AN within one
speciﬁc geographical region and did not examine IHS
healthcare users [12, 24].
Our low CRC screening prevalence requires explana-
tion. Attitudes and perceptions play an important role in
people who decide to undergo screening. The lack of
understanding CRC screening beneﬁts [26–28], concerns or
embarrassment [29], and implications from receiving a
diagnosis of CRC [26–28] all contribute to lower screening
prevalence. Some of these issues have been reported in
small studies of AI/AN [12, 13]. Also, refusal and lack of
adherence to screening is higher in minority populations
0
1
2
3
4
5
6
% of IHS Patients 
Screened
FOBT DCBE Flexible
Sigmoidoscopy
Colonoscopy
CRC Screening Method
Alaska
East
Northern Plains
Pacific Coast
Soutwest
All Regions
Fig. 2 Proportion of eligible, average-risk AI/AN IHS patients, aged
50–80 years, who underwent CRC screening during 1996–2004
stratiﬁed by method and IHS geographical region
Table 4 CRC screening predictors in average-risk AI/AN IHS
patients, aged 50–80 years
Predictor Relative risk
(95% conﬁdence interval)
a
Female sex 1.6 (1.4–1.7)
IHS geographic region
Paciﬁc Coast 1.0
Alaska 2.5 (2.2–2.8)
East
b 1.1 (0.9–1.2)
Southwest 0.5 (0.5–0.6)
Northern Plains 0.4 (0.3–0.4)
Calendar year
c
1999–2000 1.0
2001–2002 0.2 (0.2–0.3)
2003–2004 1.5 (1.4–1.7)
Number of comorbid medical conditions
None 1.0
One
b 12.9 (1.0–176.0)
Two 18.2 (1.3–247.0)
Three or more 34.0 (2.5–463.0)
Number of primary care visits
d
One 1.0
Two 0.8 (0.7–0.9)
Three or more 0.5 (0.4–0.5)
a P value\0.001 unless stated otherwise
b P value[0.05
c Predictors for years prior to 1999 were not utilized in the Poisson
regression model given that there was very little CRC screening docu-
mented during this timeframe (27 cases) and only one screening method
(colonoscopy) was allowed to be performed during this time
d Primary care visits includes patients with medical visits in the following
clinics: Cancer Screening, Chronic Disease, Diabetes, Internal/General
Medicine, Elder Care, Family Practice, Gastroenterology/Hepatology,
General Preventative, Men’s and Women’s Health Screening, Obstetrics/
Gynecology, Traditional Medicine, or Wellness clinics
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123[30–32]. However, this has yet to be directly studied in the
AI/AN community and such issues may play a role in the
low CRC screening prevalence we observed. Furthermore,
IHS healthcare providers may not recommend CRC
screening, may be unfamiliar with CRC screening guide-
lines, or they may be impeded by insufﬁcient funding.
Another potential barrier to CRC screening may be a
limited capacity to provide endoscopic services for
screening. Access to specialty care within IHS can be
challenging due to limited resources and geographic loca-
tion thereby limiting the number of trained physicians able
to perform endoscopy for screening purposes.
CRC screening predictors may shed light on the cause of
the low prevalence of screening we found. We conﬁrmed
that geographic region and sex were important predictors,
both of which have been reported previously [12, 13, 24].
One of the strongest predictors for screening pertained to
geography. Regional differences in CRC screening are key
in that they not only reﬂect the diversity of the AI/AN
community, but exemplify potential differences in access
to CRC screening, ﬁnancial resources, and cultural beliefs
about screening. Additionally, regional disparities draw
attention to programs aimed at increasing screening within
particular communities as well as individual screening
preferences by local IHS leadership. Our ﬁnding that
residing in Alaska was one of the strongest screening
predictors reﬂects a concerted effort by the tribal leader-
ship, IHS, and the Centers for Disease Control and Pre-
vention to increase CRC screening in this community using
endoscopy [33, 34]. A similar result was reﬂected in the
Paciﬁc Coast where there has been an increased effort to
use FOBT for CRC screening [35].
There was a trend toward increased screening with a
greater number of co-morbid medical conditions compared
to lower CRC screening in patients with multiple primary
care visits. Such a ﬁnding appears contradictory to what is
reported in the literature [36]. One possible explanation is
that patients in our study with multiple primary care visits
may represent a distinct group with other social issues or
complex medical problems that are not reﬂected in the
number of co-morbid medical conditions. AI/AN have
higher rates of substance abuse, tobacco usage, and obesity
resulting in more complex medical and social problems
compared with other groups [14]; all conditions not easily
captured in the number of co-morbid medical conditions.
Also, healthcare providers may be less inclined to recom-
mend CRC screening to patients with more primary care
visits as this may represent a subset of patients who are less
compliant with their medications, have a poorer under-
standing of their disease process, or have diseases that may
preclude them from invasive CRC screening.
Another ﬁnding of our study was the high CRC inci-
dence estimated among AI/AN IHS users. The age-
adjusted CRC incidence rate of 227 cancers per 100,000
person-years is higher than previously reported [2]. In
comparison, using 2006 SEER data, age-adjusted CRC
incidence for the U.S. population for individuals older
than 50 years was 150 cancers per 100,000; for African-
Americans it was 184 cancers; and for Caucasians it was
148 cancers [37]. Our rate should be interpreted with
caution. Our study only examined IHS patients and was
limited to a speciﬁc age range. We relied on ICD-9 codes
Table 5 New cases of colorectal cancer documented in AI/AN
patients, aged 50–80 years, who utilized IHS from 1996 to 2004
Variable New cases of
colorectal
cancer (%, 95% CI)
Sex
a,b
Male (n = 127,095) 1,687 (1.3, 1.3-1.4)
Female (n = 156,543) 1,870 (1.2, 1.1-1.3)
Age at cancer diagnosis (years)
b
50-54 (n = 144,689) 607 (0.4, 0.4-0.5)
55-59 (n = 113,960) 557 (0.5, 0.5-0.5)
60-64 (n = 92,106) 686 (0.8, 0.7-0.8)
65-69 (n = 72,085) 592 (0.8, 0.8-0.9)
70-74 (n = 53,076) 584 (1.1, 1.0-1.2)
75-80 (n = 38,710) 532 (1.4, 1.3-1.5)
IHS geographic region
b
Alaska (n = 23,385) 680 (2.9, 2.7-3.1)
East (n = 81,259) 1071 (1.3, 1.2-1.4)
Northern Plains (n = 56,537) 736 (1.3, 1.2-1.4)
Paciﬁc Coast (n = 37,346) 351 (0.9, 0.8-1.0)
Southwest (n = 85,190) 720 (0.9, 0.8-0.9)
Number of comorbid medical conditions
b
None (n = 13,019) 35 (0.3, 0.2-0.4)
One (n = 22,514) 196 (0.9, 0.8-1.0)
Two (n = 23,287) 320 (1.4, 1.2-1.5)
Three or more (n = 224,897) 3,007 (1.3, 1.3-1.4)
Number of medical visits
b,c
One (n = 24,945) 155 (0.6, 0.5-0.7)
Two (n = 22,502) 139 (0.6, 0.5-0.7)
Three or more (n = 236,270) 3,264 (1.4, 1.3-1.4)
Patient underwent CRC screening
b
Unscreened (n = 278,056) 3,517 (1.3, 1.2-1.3)
Screened (n = 5,661) 41 (0.7, 0.5-1.0)
Overall (n = 283,717) 3,558 (1.3, 1.2-1.3)
Incidence rate (per 100,000 person-years) 242
Age-adjusted incidence rate (per 100,000
person-years)
227
a There were 79 patients with unknown gender, 1 of whom had colon
cancer
b Differences between variables within subgroup were statistically
signiﬁcant, P\0.001
c Includes any IHS medical visit
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123to document CRC rather than on a histological diagnosis as
has been performed in previous analyses [2]. Also, mis-
coding of CRC using ICD-9 codes may occur using RPMS
data. To our knowledge, there are no studies available that
directly assess the reliability of ICD-9 coding and the
diagnosis of CRC in IHS patients using RPMS data. A
separate study that examines ICD-9 coding in RPMS and
CRC diagnosis with conﬁrmation using IHS medical
records would be helpful but has yet to be conducted.
Finally, persons eligible for IHS services but less likely to
seek them, such as those not experiencing symptoms, are
less likely to be included in the analysis.
While our overall CRC incidence for AI/AN was high,
more strikingly, signiﬁcant geographical variation existed
in CRC detected among IHS AI/AN. This variation was
most notable among Alaskan Natives who had three times
the CRC incidence rate of other regions. Our ﬁndings that
geography was linked with higher rates of CRC have been
illustrated in previous studies [2, 38]. One potential reason
for this discrepancy in CRC incidence may relate to dif-
ferential prevalence of CRC screening. CRC screening is a
vital tool in the early detection of CRC and the removal of
precancerous lesions (polyps) and has led to important
reductions in CRC incidence and mortality [1, 4]. How-
ever, AN had nearly ten times the rate of screening com-
pared with other regions indicating that other factors aside
from screening may profoundly inﬂuence CRC incidence
among this group. A number of alternate theories have
been postulated to account for these differences in CRC
incidence. One possible reason is that geography itself has
shaped the risk for CRC in AN: Alaska is separated from
the transcontinental U.S. by signiﬁcant distances and this
can affect CRC incidence in many arenas in comparison
with other regions of the U.S. Lifestyle factors may con-
tribute to the development of CRC. For example, tobacco
usage [39, 40], higher alcohol consumption and binge
drinking [39, 40], sedentary lifestyle [39], and obesity [39,
41] increase one’s risk for CRC; all of which have been
consistently shown to be signiﬁcantly higher in AN com-
pared with other AI in IHS regions [14]. Also, geography
encompasses cultural differences that may include diet and
use of alternative medications which may impact CRC
incidence. Again, AN have diets low in fruits and vegeta-
bles [14] which may increase their risk for CRC compared
to other AI [42]. Lastly, varying CRC incidence among
regions may also reﬂect a genetic component in the
development of CRC among AI/AN. All these factors,
either separately or acting in concert with one another, can
play a role in the higher CRC incidence noted in AN.
Several limitations may inﬂuence the interpretation
of our study. First, methodological considerations may
have underestimated CRC screening prevalence. In par-
ticular, distinguishing between screening and diagnostic/
surveillance examinations using RPMS data is challenging.
We systematically excluded patients with symptoms/dis-
eases that would have resulted in further endoscopic
evaluation for non-CRC screening purposes thus resulting
in a more representative patient population of average-risk
individuals. Second, IHS provides healthcare to approxi-
mately 57% of U.S. AI/AN that are mostly a rural popu-
lation thereby limiting the generalizability of our results.
Third, a subset of IHS patients may have received CRC
screening from another health care facility outside of IHS
for which we could not account. This data are exceedingly
difﬁcult to capture and has not been extensively studied. To
date, the only study to examine this issue was a small pilot
study that examined the medical records of IHS patients
identiﬁed as having undergone CRC screening in ﬁve IHS
facilities. This data demonstrated that only a small fraction
of patients underwent screening at a facility outside of IHS
(0.6%) [43]. The number of IHS users who may select to
have CRC screening at outside facilities may be higher
than this estimate but currently such information is
unavailable. Thus, while patients do have the option to
obtain CRC screening at facilities outside of IHS limited
data suggest that this number is small and unlikely to affect
our results. Currently, a survey of IHS sites is being con-
ducted which is assessing CRC capacity and will provide a
much better estimate of what is performed within IHS
healthcare facilities versus referral. A fourth limitation is
that data beyond 2004 may reﬂect a more accurate repre-
sentation of CRC screening prevalence for AI/AN. How-
ever, our study period overlaps with other studies, few
studies exist examining screening in AI/AN after 2004, and
the available studies do so only from a regional perspective
[12, 13]. Also, we used coding data to represent CRC
screening and this raises issues of systematic and random
coding errors occurring in our dataset. Only one small (618
patients), unpublished study has addressed this issue. In
this study, the authors discovered a 25% misclassiﬁcation
rate between screening and diagnostic colonoscopy for IHS
patients. Further examination of their data revealed a
miscoding rate of only 7.6% and was based overwhelming
on the use of one speciﬁc ICD-9 code that we did not
utilize to capture screening methods for our study. Also,
this study did not exclude patients who had previously
documented symptoms that may have led to a diagnostic
endoscopy, a method that we employed in our analysis
[43]. Lastly, a vast majority of IHS AI/AN individuals had
multiple comorbid medical conditions which may intro-
duce some ascertainment bias into our results. However,
this ﬁnding is not surprising given that AI/AN are dispro-
portionally affected by more chronic diseases such as
diabetes, hypertension, heart disease, and several forms of
cancer when compared with other racial groups [4, 14].
Moreover, as previously discussed, AI/AN have elevated
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123rates of long-term tobacco usage and alcohol consumption
compared with other groups thus predisposing them to the
multiple medical consequences/diseases of such usage
which is likely reﬂected in our data. Also, patients with
chronic diseases are more likely to seek health care and
thus be a part of the IHS medical system as compared with
healthy, asymptomatic patients who are less likely to seek
care. Despite these limitations, we believe our study adds
an important perspective in portraying CRC screening
prevalence among average-risk AI/AN.
In conclusion, CRC screening among asymptomatic,
average-risk AI/AN who used IHS for medical care was
extraordinarily low from 1996 to 2004. Unexplained dis-
crepancies exist in CRC screening prevalence based on sex,
geographic location, and health-care utilization. The low
prevalence of recommended screening for AI/AN served
by IHS is disturbing and highlights potential areas where
efforts for awareness and access to CRC screening should
be directed.
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